Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
DUBLIN, Ireland, Oct. 11, 2016 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its third-quarter 2016 financial results will be released on Monday, November 7, 2016. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 98231038. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 98231038.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, rheumatology and primary care business units. Horizon Pharma's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations [email protected] Tina Ventura Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
